An observational study in Diabetes Mellitus Type 2 in Obese, sponsored by Hasan Kalyoncu University. Recruiting at 2 sites in Turkey. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Hasan Kalyoncu University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 353 studies in Obesity with a site in Turkey, this one is the 157th largest by planned enrollment of the 160 observational ones that give a count, is one of 54 that started in 2022, is one of 160 observational ones, reaches primary completion later than 0 of the 89 other live ones, and was the 134th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Ages 18–65 · Women only
Gazi University · Sites in Turkey
Ages 50–60 · Women only
Duzce University · Sites in Turkey
Ages 18+
Pamukkale University · Sites in Turkey
Ages 18–60 · Women only
Kocaeli University · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 54 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 64 across the 192 interventional studies, 82 across the 160 observational. Of the 237 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 353 have an industry lead sponsor. The 10 most frequent:
Hasan Kalyoncu University is the lead sponsor of 167 studies on the registry; 33 are open to participants now.
Hasan Kalyoncu University has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
33 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 353 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The increase in the prevalence of diabetes and the loss of various organs and functions in the individual as a result of complications caused by diabetes affect the life expectancy and quality of individuals, and cause social and economic losses affecting the whole society. For this reason, the individual management of the diabetic patient is important in terms of ensuring effective participation and compliance in treatment and care. Patients must have knowledge, skills and positive attitudes in order to successfully comply with diabetes treatment. Patients are in compliance with diabetes treatment; they encounter some barriers such as medication barriers, barriers to self-monitoring, knowledge and belief barriers, barriers to diagnosis, barriers in relations with health professionals, barriers to lifestyle change, barriers to coping with diabetes, and barriers to getting advice and support. The American Diabetes Association (ADA) states that self-monitoring of blood sugar is important in ensuring glycemic control and preventing hyperglycemia and asymptomatic hypoglycemia. Reiki is applied as an alternative and complementary treatment method. Reiki application, when used together with pharmacological methods, chronic fatigue, diabetic neuropathy, pain caused by surgery, cancer treatment, symptoms of cardiovascular diseases, emotional disorders such as anxiety, depression, acute or chronic pain, infertility-related problems, neurodegenerative disorders, AIDS, autism and developmental disorders, Crohn's disease, irritable bowel syndrome, traumatic brain injury and has been shown to improve health problems such as fatigue.
In the literature, the effects of reiki have been examined in patient groups with different chronic diseases, but no study has been found on obese individuals with Type 2 diabetes. Therefore, reikinin in obese individuals with Type 2 diabetes; This study is planned to determine whether it has an effect on compliance with diabetes treatment, eating behaviors, anxiety levels and changes in metabolic values.
The increase in the prevalence of diabetes and the loss of various organs and functions in the individual as a result of complications caused by diabetes affect the life expectancy and quality of individuals, and cause social and economic losses affecting the whole society. Diabetes with poor management causes many acute and chronic complications. Keeping diabetes under control seriously affects the occurrence of microvascular and macrovascular complications, which develop over years and seriously affect life. Compliance with diabetes treatment; nutrition therapy, regular exercise program, patient self-monitoring, medication, access to health facilities and patient education. With regular monitoring and monitoring of these parameters, compliance with a successful diabetes treatment is improved. The basis of compliance with diabetes treatment is determined by the attitudes and behaviors of patients regarding their own health. For this reason, the individual management of the diabetic patient is important in terms of ensuring effective participation and compliance in treatment and care. Patients must have knowledge, skills and positive attitudes in order to successfully comply with diabetes treatment. Patients are in compliance with diabetes treatment; they encounter some barriers such as medication barriers, barriers to self-monitoring, knowledge and belief barriers, barriers to diagnosis, barriers in relations with health professionals, barriers to lifestyle change, barriers to coping with diabetes, and barriers to getting advice and support. The inability of the individual to cope with these obstacles adequately causes problems in compliance with diabetes treatment. One of the most important points in compliance with diabetes management and treatment is self-monitoring of blood glucose. The American Diabetes Association (ADA) states that self-monitoring of blood sugar is important in ensuring glycemic control and preventing hyperglycemia and asymptomatic hypoglycemia. HbA1c levels were found to be lower in patients who measured their blood glucose more frequently. In patients with poor diabetes management and persistent hyperglycemia, there is an increase in HbA1c value. A 1% increase in HbA1c value is accepted as a risk in the formation of complications. Reiki is applied as an alternative and complementary treatment method. Reiki application, when used together with pharmacological methods, chronic fatigue, diabetic neuropathy, pain caused by surgery, cancer treatment, symptoms of cardiovascular diseases, emotional disorders such as anxiety, depression, acute or chronic pain, infertility-related problems, neurodegenerative disorders, AIDS, autism and developmental disorders, Crohn's disease, irritable bowel syndrome, traumatic brain injury and has been shown to improve health problems such as fatigue (43).
In the literature, the effects of reiki have been examined in patient groups with different chronic diseases, but no study has been found on obese individuals with Type 2 diabetes. Therefore, reikinin in obese individuals with Type 2 diabetes; This study is planned to determine whether it has an effect on compliance with diabetes treatment, eating behaviors, anxiety levels and changes in metabolic values.
Having been diagnosed with Type 2 diabetes at least 6 months ago, Body mass index ≥ 30 kg/m², Being on oral therapy or using insulin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals who will undergo Reiki for 12 weeks
Other: REİKİ
control group
Reiki is applied as an alternative and complementary treatment method.
"Reiki has a positive effect on adherence to treatment, eating behaviors and metabolic values in obese individuals with type 2 diabetes.
Metabolic changes in the patient before and after reiki
Time frame: 12 weeks
Blood glucose level
HbA1c change in the patient before and after reiki
Time frame: 12 weeks
Blood cholesterol level
Blood cholesterol exchange level
Time frame: 12 weeks
Blood pressure
Blood pressure status
Time frame: 12 weeks
Body mass index
Body mass index change
Time frame: 12 weeks
Belly circumference measurement
waist circumference will be measured with a tape measure
Time frame: 12 weeks
Anxiety level change
TO BE EVALUATED BY SCALE
Time frame: 12 weeks
Change in eating behavior
The change in eating behavior will be evaluated with a scale
Time frame: 12 weeks
Change in adherence to treatment
change in adherence to treatment will be evaluated with a scale
Time frame: 12 weeks
Plan to share: Yes
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Jul 2023, 10 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 10 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.